Shots: Fujifilm to receive upfront, license fee along with royalties on sales of the therapy. Dr. Reddy’s and GRA to get the exclusive right to develop & commercialize Avigan globally (Ex- Japan). Additionally, Dr. Reddy’s would have exclusive rights for the therapy in India Fujifilm will provide pre/ clinical data of Avigan to Dr. Reddy’s […]Read More
Shots Gilead signs a non-exclusive licensing agreement with Zydus to manufacture and distribute remdesivir, under which Zydus to receive the manufacturing know-how from Gilead to manufacture the API for remdesivir and the finished product and market it in 127 countries, including India The license is royalty-free until another pharmaceutical product or vaccine receives the US […]Read More
Shots: Dr. Reddy’s acquires Wockhardt’s select divisions of its branded generics business in India and other international territories of Nepal, Sri Lanka, Bhutan and Maldives for ~$259M (Rs.1850 crores) The focus of the acquisition is to boost Dr. Reddy’s presence in the high growth therapy areas with the addition of Wockhardt’s Practin, Zedex, Bro-zedex, Tryptomer […]Read More
Shots: Dr. Reddy’s acquires a portfolio of 42 approved, non-marketed Abbreviated New Drug Applications (ANDAs) in the US, including >30 generics injectable The focus of the acquisition is to enhance Dr. Reddy’s injectable portfolio in the US and globally Dr. Reddy’s will launch the products within the next one to two years and according to […]Read More
Shots: Therapiva to get hold of its all stocks including its related fixed assets, current assets, current liabilities, and employees The division is in response to focus on forming manufacturing operations and optimizing its cost structures and strengthening Therapiva’s API portfolio Therapiva Private Ltd is a joint venture between Omnicare Drugs India Private Limited (subsidiary […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
